In yesterday’s Wall Street session, Zomedica Corp (AMEX:ZOM) shares traded at $0.14, up 2.03% from the previous session.
ZOM stock price is now -0.35% away from the 50-day moving average and -22.07% away from the 200-day moving average. The market capitalization of the company currently stands at $132.78M.
With the price target of $6, Dawson James recently initiated with Buy rating for Zomedica Corp (AMEX: ZOM).
In other news, POWERS JOHNNY D, Director bought 100,000 shares of the company’s stock on Dec 15 ’23. The stock was bought for $16,500 at an average price of $0.17. Upon completion of the transaction, the Director now directly owns 1,950 shares in the company, valued at $273.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 17 ’23, Director POWERS JOHNNY D bought 100,000 shares of the business’s stock. A total of $16,600 was incurred on buying the stock at an average price of $0.17. This leaves the insider owning 1,850,000 shares of the company worth $0.26 million. A total of 1.59% of the company’s stock is owned by insiders.
During the past 12 months, Zomedica Corp has had a low of $0.12 and a high of $0.25. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 17.12, and a quick ratio of 16.57. The fifty day moving average price for ZOM is $0.1354 and a two-hundred day moving average price translates $0.1736 for the stock.
The latest earnings results from Zomedica Corp (AMEX: ZOM) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at $0, inline with analysts’ expectations of $0. This compares to -$0.01 EPS in the same period last year. The net profit margin was -62.21% and return on equity was -5.64% for ZOM. The company reported revenue of $6.35 million for the quarter, compared to $4.78 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.89 percent. For the current quarter, analysts expect ZOM to generate $7M in revenue.
